Get started
Work

Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors

Year: 2016
Type: article
Study design: Clinical Trial
DOI: 10.1007/s00280-016-2998-6
Authors: Shivaani Kummar, Alice Chen, Martin Gutierrez, Thomas D. Pfister, Lihua Wang, Christophe Redon, William M. Bonner, William Yutzy, Yiping Zhang, Robert J. Kinders, Jiuping Ji, Deborah Allen, Joseph M. Covey, Julie L. Eiseman, Julianne L. Holleran, Jan H. Beumer, Larry Rubinstein, Jerry Collins, Joseph Tomaszewski, Ralph Parchment, Yves Pommier, James H. Doroshow
Institutions: National Institutes of Health, National Cancer Institute, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc. (United States), Center for Cancer Research, UPMC Hillman Cancer Center
Language: English
Open Access status: green
Awards: G1529121756, G2474977437, G386607036, G5888954722, G741073515, NCI ETCTN Pittsburgh Cancer Consortium (PCC)
OpenAlex ID: W2390517379
FWCI: 2.859
Cites: 18
Cited by: 40
Related to: 10